Top Artificial Intelligence-Based Healthcare Mobile Apps and Their Use Cases

Dermatology

Development of Gene Therapies in Dermatology

What is Gene Therapy and Is the Skin Suitable for Gene Therapy? Since its first discovery, conceptualization in 1972, and successful application in 1990 by W. French Anderson, gene therapy has been...

Oct 18, 2021

recent-biotech-pharma-news-for-brickell-bms-amydis-gensight-cybrexa
Brickell to Submit New Drug Application to FDA; Twin Health Raises $140M; BMS’ Deucravacitinib; Lando Biopharma’s LABP-104 gets Approval; NIH Grant of $ 3 M to Amydis; FDA Grant to GenSight’ GS030

Brickell Plans to Submit New Drug Application to FDA for gel Brickell Biotech will request the FDA in mid-2022 to approve its gel for excessive underarm sweating after decreasing sweat production and disease severity in two pivotal trials.  The gel achieved statistical significance in lessening the sever...

Find More
pharma-biotech-news-updates-for-innovent-biohaven-delix-intracellular-therapies
UNION Therapeutics-Innovent’s collaboration; Delix Therapeutics bags $ 70 M; Biohaven’s Verdiperstat clinical trial result; Intra-Cellular’s CAPLYTA Phase III study

Innovent, UNION Therapeutics Set to Advance Dermatology Market in China  Innovent Biologics and UNION therapeutics have announced a strategic and licensing collaboration to develop and commercialize Orismilast, a next-generation PDE4 inhibitor for inflammatory dermatology conditions in China. Orismilast ...

Find More
latest-biotech-healthcare-pharma-news-updates-aelis-farma-alcyone-progentec-gsk-kozin
Aelis Farma pockets $30M; Alcyone unveils $23M for AAV gene therapies; Progentec and GSK collaborate; Kozin bags $60M

Aelis Farma pockets USD 30 Million upfront in cannabis use disorder deal with Indivior Indivior speculates that Aelis Farma has what it takes to bring cannabis use disorder therapy into the clinic with a USD 30 million upfront rights agreement. Aelis, clinical-stage French biotech zeroed in on brain disorders...

Find More

More Views & Analysis

absssi-pipeline-analysis
Pharma Companies Foray into the ABSSSI Market to Develop Novel Antibiotics and Tackle Antibiotic Resistance

The introduction of antibiotics subsequently transformed the healthcare industry bringing on the table several life-saving drugs. Long 60 years back, when the first antibiotic, Penicillin, came into existence, a new era of medicine with the potential to cope up with bacterial infections began.  However, the...

Find More

recent-pharma-biotech-lifescience-healthcare-news-updates-for-vertex-virta-kalvista-ovid-crispr-therapeutics
Vertex leads in CRISPR Therapeutics deal; Update for Phase 2 clinical trial of KVD824; Ovid dumps lead program; Virta Health pulls in $133M

Vertex leads in CRISPR Therapeutics partnership with USD 900 Million upfront Vertex has boosted a deal with CRISPR Therapeutics to USD 900 million upfront as the companies compete against bluebird bio to the market with a novel gene-editing therapy for sickle cell disease and beta-thalassemia called CTX001. B...

Find More

Merck, Gilead teams up for HIV treatment; Bright Future for Sanofi/Regeneron’s Libtayo; Roche acquires GenMark; FDA okays Melinta’s Kimyrsa
Merck, Gilead teams up for HIV treatment; Bright Future for Sanofi/Regeneron’s Libtayo; Roche acquires GenMark; FDA okays Melinta’s Kimyrsa

Merck, Gilead  to co-develop combined HIV treatments Merck and Gilead have announced a collaboration to investigate Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, into a two-drug regimen.  Both...

Find More

recent-pharma-biotech-news-updates-happenings-for-beam-grail-quest-diagnostics
Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer

Beam adds to drug delivery stable with USD 120 Million GuideTx buy Beam Therapeutics has taken over a startup whose technology could proffer the biotech’s genetic medicines to more tissues in the body, widening the potential to approach more diseases. Beam announced that it paid USD 120 million upfront to acq...

Find More

recent-pharma-biotech-happenings-for-bms-prothena-canon-medical-immunovant
Plaque psoriasis drug outshines in phase III trial; Immunovant announces pause in trial of IMVT-1401; Prothena brings AL amyloidosis drug back; Canon Medical expands its MRI AI programs

Plaque psoriasis drug outshines the competition in phase III trial Bristol Myers Squibb’s psoriasis drug, the TYK2 inhibitor outshone placebo and Amgen’s Otezla in a second phase 3 study, setting discussions with regulators. The study, known as POETYK PSO-2, trialled the drug, deucravacitinib, against placebo...

Find More

Horizon, Viela Deal; Concert Schizophrenia Drug Flop; Gilead, Gritstone Deal
Horizon, Viela Deal; Concert Schizo Drug Flop; Gilead Deals with Arcus and Gritstone

Horizon Therapeutics Bolsters its Rare Disease Portfolio in a $3B Viela Bio Buyout Horizon Therapeutics has announced to acquire Viela Bio for about $3.1 billion to augment its portfolio and pipeline of treatments for rare diseases. The shares of Viela Bio skyrocketed more than 52% in premarket trading after the...

Find More

Though Covid-19 has a significant impact on the supply chain, input costs, logistics, and raw materi.....

Find More

Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease that results in systemic inflamma.....

Find More

Acute myeloid leukemia (AML), also called acute myelogenous leukemia and acute nonlymphocytic leukem.....

Find More

Immunotherapies, a potentially life-saving therapy, have benefitted several patients suffering from .....

Find More

Uremic Pruritusis also known as chronic kidney disease-associated pruritus (CKD-aP), is a chronic it.....

Find More

Healthcare Performance Improvement provides proven methods for sustaining and building a culture of .....

Find More